Search
rimegepant (Nurtec ODT)
Indications:
- prevention &/or treatment of migraine attack [1,2,3,4]
Pharmacokinetics:
- gepants able to cross the blood brain barrier
Adverse effects:
- nausea [5]
Mechanism of action:
- CGRP receptor antagonist
- gepants do not cause vasoconstriction
General
gepant
heterocyclic compound, 2 rings
Database Correlations
PUBCHEM correlations
References
- George J.
Oral CGRP Inhibitor Helps Relieve Migraine Attack
About 20% report being pain-free within 2 hours.
MedPage Today. April 26, 2018
https://www.medpagetoday.com/meetingcoverage/aan/72559
- Lipton RB, Croop R, Stock EG et al
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist,
for Migraine.
N Engl J Med. 2019 Jul 11;381(2):142-149.
PMID: 31291516 Clinical Trial.
- Croop R, Goadsby PJ, Stock DA et al
Efficacy, safety, and tolerability of rimegepant orally disintegrating
tablet for the acute treatment of migraine: a randomised, phase 3,
double-blind, placebo-controlled trial.
Lancet. 2019 Aug 31;394(10200):737-745.
PMID: 31311674 Clinical Trial.
- George J
First Drug Approved for Acute and Preventive Migraine Treatment.
Rimegepant becomes first oral CGRP antagonist to earn nod for migraine prevention.
MedPage Today May 28, 2021
https://www.medpagetoday.com/neurology/migraines/92837
- Windle ML
Rapid Rx Quiz: Headache Medications
Medscape. Sept 12, 2022
https://reference.medscape.com/viewarticle/980181